Millennium Management LLC lessened its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 18.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,065 shares of the company’s stock after selling 21,909 shares during the quarter. Millennium Management LLC owned about 0.17% of Apogee Therapeutics worth $3,820,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. EntryPoint Capital LLC lifted its stake in shares of Apogee Therapeutics by 44.7% in the 1st quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock worth $133,000 after acquiring an additional 617 shares during the period. Kennedy Capital Management LLC acquired a new position in Apogee Therapeutics during the 1st quarter worth approximately $212,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Apogee Therapeutics during the 2nd quarter worth approximately $143,000. Ameritas Investment Partners Inc. raised its stake in shares of Apogee Therapeutics by 111.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock worth $274,000 after buying an additional 2,172 shares in the last quarter. Finally, Principal Financial Group Inc. acquired a new stake in shares of Apogee Therapeutics in the 1st quarter valued at approximately $339,000. 79.04% of the stock is owned by institutional investors and hedge funds.
Apogee Therapeutics Price Performance
Shares of APGE stock opened at $56.94 on Monday. Apogee Therapeutics, Inc. has a 1-year low of $14.19 and a 1-year high of $72.29. The business’s fifty day moving average price is $50.48 and its 200 day moving average price is $48.82. The firm has a market capitalization of $3.33 billion, a PE ratio of -10.85 and a beta of 2.75.
Insider Buying and Selling at Apogee Therapeutics
In related news, insider Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $56.26, for a total transaction of $374,972.90. Following the completion of the sale, the insider now owns 274,128 shares in the company, valued at approximately $15,422,441.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 40,000 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $40.62, for a total transaction of $1,624,800.00. Following the transaction, the chief executive officer now owns 1,434,487 shares of the company’s stock, valued at $58,268,861.94. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $56.26, for a total value of $374,972.90. Following the completion of the sale, the insider now directly owns 274,128 shares of the company’s stock, valued at approximately $15,422,441.28. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 146,665 shares of company stock worth $7,058,635. 36.10% of the stock is owned by corporate insiders.
Apogee Therapeutics Profile
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Featured Stories
- Five stocks we like better than Apogee Therapeutics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- Want to Profit on the Downtrend? Downtrends, Explained.
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Want to see what other hedge funds are holding APGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report).
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.